Table 2.
Publications of aptamer-mediated nano-vehicles, physico-chemical and tumoricidal characterizations in the recent years.
| Aptamer /Target |
Type (bp) |
Physico-chemical Property | Anti-tumor Potency | Reference | ||||
|---|---|---|---|---|---|---|---|---|
| Vehicle | Drug | Drug loading | Release profile | Cancer model(cell line) | Study type | |||
| AS1411 /NCL |
DNA (28) | Triblock co- polymer NPs* | Dox | LP 3.64% | pH-responsive: 70.30% in PBS, 48h |
MCF-7, PANC-1 | In vitro | Lale SV, et al. 2014 |
| DNA (28) | Carbon nanotube | Dox | DNS | DNS | Nude mice bearing xenograft (PC3 cell) | In vitro & In vivo |
Zhang H, et al. 2014 | |
| DNA (38) | Liposome | Dox | LP 12.5% | Hydrolytic release: 10% in plasma, 24h |
Nude mice bearing xenograft (MCF-7) | In vitro & In vivo |
Xing H, et al. 2013 | |
| DNA (26) | Mesoporous silica NPs | Dox | LP 4.6% | pH-responsive: 72% in PBS, 50h |
MCF-7,MDA MB-231 | In vitro | Li LL, et al. 2012 | |
| DNA (26) | PLGA-lecithin-PEG NPs | Ptx | EE 60.93% | Hydrolytic release: 94% in PBS, 120h |
GI-1, MCF-7 | In vitro | Aravind A, et al. 2012 | |
| DNA (28) | PEG-PLGA NPs | Ptx | EE 44.7%, LP 1.02% |
Hydrolytic release: 78.4% in PBS, 84.1% in plasma, 12d | Nude mice bearing xenograft (C6 glima cell) | In vitro & In vivo |
Guo JW, et al. 2011 | |
| DNA (26) | Silica-coated gold nanorods | Dox | LP 3.8% | photothermo-responsive release | MCF-7 | In vitro | Yang XJ, et al. 2012 | |
| A10 /PSMA |
RNA (57) | Unimolecular micelles NPs | Dox | LP 10.4% | pH-responsive: 91% in PBS, 45h |
Nude mice bearing xenograft (CWR22Rv1 cells) | In vitro & In vivo |
Xu WJ, et al. 2013 |
| RNA (57) | PLA-PLGA NPs | Platinum Docetaxel | Pt: EE95%, LP 5%; Dtx: EE80%, LP 1%. |
Hydrolytic release: 98% Dxtl and 80%, Pt in PBS, 72h | LNCaP | In vitro | Kolishetti N, et al. 2010 | |
| RNA (57) | PLGA NPs | Platinum | LP 5% | DNS | Nude mice bearing xenograft (LNCaP) | In vivo | Dhar S, et al. 2010 | |
| RNA (91) | Golden-NPs | Dox | Apt-Dox ratio: 2:15 (molar) | Hydrolytic release: 52% in PBS, 24h |
LNCaP | In vitro | Kim, D, et al. 2010 | |
| RNA (57) | QD-Apt-drug conjugate | Dox | QD-Apt/Dox ratio: 1/7 (molar) | DNS | LNCaP | In vitro | Bagalkot V et al. 2009 | |
| SZTI01 /PSMA |
DNA (48) | Dimeric apt- drug complex | Dox | Apt-Dox ratio: 1:4 (molar) | Hydrolytic release: 40% in PBS, 6h |
C4-2 cells | In vitro | Boyacioglu O, et al. 2013 |
| 5TR1 /MUC1 |
DNA (25) | Apt-SPION complex | Epirubicin | LP 2.27% | DNS | BALB/c mice bearing xenograft (C26 cells) | In vitro & in vivo |
Jalalian SH, et al. 2013 |
| MA3 /MUC1 |
DNA (86) | Apt-drug conjugate | Dox | Apt-dox ratio: 1/10 (molar) | DNS | A549 lung cancer, MCF-7 | In vitro | Hu Y, et al. 2012 |
| Apt /MUC1 | DNA (25) | DNA Icosahedral | Dox | LP 40% | DNS | CHO-K1, MCF-7 | In vitro | Chang M, et al. 2011 |
| S2.2 /MUC1 |
DNA (19) | PLGA NPs | Ptx | EE 83.6%, LP 4.2% | Hydrolytic release: 65% in PBS, 48h |
MCF-7,HepG2 | In vitro | Yu CC , et al. 2011 |
| Apt /MUC1 | DNA (25) | QD-Apt-Dox conjugate | Dox | QD-dox ratio: 1/46 (molar) | pH-responsive: 35%, 5h |
athymic nu/nu mice bearing xenograft (A2780/AD cells) | In vitro & in vivo |
Savla R, et al. 2011 |
| Sgc8c /PTK7 | DNA (41) | PLGA hybrid NPs | Ptx, Dox |
LP 3.5%, EE35%. | DNS | CEM cells and Ramos cells | In vitro | Huang FJ, et al. 2014 |
| DNA (41) | Apt-drug conjugate | Fluorouracil | Apt/drug ratio: 1/5 (molar) | Photo-controllable release | HCT116 cells | In vitro | Wang RW, et al. 2014 | |
| DNA (41) | Apt -drug Nanotrain | Dox | Apt-NTr/drug ratio: 1/50 (molar) | DNS | NOD. Cg-Prkdc mice bear- ing xenograft (CCRF-CEM) | In vitro & in vivo |
Zhu GZ, et al. 2013 | |
| DNA (41) | AuNR-based Nanogel | Dox | DNS | Photothermo-responsive: 74%, 50min | CCRF-CEM cells, Ramos cells | In vitro | Kang HZ, et al. 2011 | |
| DNA (41) | Lipid-coated droplet | Dox | EE 50.6%, LP 30.4% | Ultrasound-responsive: 12% in PBS, 24h |
CCRF-CEM cell lines | In vitro | Wang CH, et al. 2012 | |
| DNA (41) | Carbon nanotube | Daunorubicin | LP 157% | pH-responsive: 60%, 72h |
Molt-4, U266 | In vitro | Taghdisi SM, et al. 2011 | |
| DNA (41) | Apt-drug conjugate | Dox | Dox/sgc8c ratio: 1/1 (molar) | DNS | CCRF-CEM cell lines | In vitro | Huang YF, et al. 2009 | |
| Ploy-Apt /PTK7 | DNA(41)n | Apt-drug conjugate | Dox | Apt/drug ratio: 1/10 (molar) | Nuclease-responsive | CCRF-CEM cells, Ramos cells | In vitro | Zhang ZQ, et al. 2013 |
| Apt /EpCAM | RNA (14) | PLGA NPs | Curcumin | EE: 89.98% | Hydrolytic release: 81% in PBS, 100h |
HT 29, HEK293T | In vitro | Li L, et al. 2014 |
| EpDT3 /EpCAM |
RNA (19) | Apt-drug conjugate | Dox | Apt-Dox ratio: 1:2 (molar) | Hydrolytic release: 37% in PBS, 6h |
Y79 and WERI-Rb1 | In vitro | Subramanian N, et al. 2012 |
| DDSs /Cyt c |
DNA (48) | Silica-shelled gold nanorods | Rotenone | LP 7.3% | Photothermo-responsive: 25%, 12h | Hela cells | In vitro | Ju EG, et al. 2014 |
| Apt /CD30 | RNA (39) | HAuNS | Dox | EE 90%, LP 30% | pH-responsive: 80% in PBS, 2h |
Karpas 299, SUDHL-1 | In vitro | Zhao NX, et al. 2013 |
| TLS11a /LH86 | DNA (63) | Apt-drug conjugate | Dox | Apt/Dox ratio: 1/25 (molar) | DNS | NOD. Cg-Prkdc mice bearing xenograft (LH86 cells) | In vitro & in vivo |
Meng L, et al. 2012 |
| HB5 /HER2 |
DNA (86) | Apt-drug conjugate | Dox | Apt-Dox ratio: 1/10 (molar) | DNS | SK-BR-3,MDA-MB-231, MCF-7 |
In vitro | Liu Z, et al. 2012 |
*triblock copolymer: [pPEGMA-PCL-pPEGMA= poly(polyethylene glycol methacrylate)-poly(caprolactone)-poly(polyethylene glycol methacrylate.
Abbreviation: SPIO, superparamagnetic iron oxide; Ptx, paclitaxel; HAuNS, hollow gold nanosphere; Dox, doxorubicin; Apt, aptamer; QD, Quantum dot; AuNR, gold nanorods; EE, encapsulation efficiency; LP, loading percentage; DNS, data not shown.